TuisRGEN • NASDAQ
add
Repligen Corp
Vorige sluiting
$161,69
Dagwisseling
$160,45 - $165,30
Jaarwisseling
$102,97 - $182,06
Markkapitalisasie
9,12 mjd USD
Gemiddelde volume
612,56 k
P/V-verhouding
6 292,04
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 188,80 m | 21,91% |
Bedryfskoste | 87,84 m | 5,00% |
Netto inkomste | 14,91 m | 2 379,97% |
Netto winsgrens | 7,90 | 1 980,95% |
Wins per aandeel | 0,46 | 6,98% |
EBITDA | 32,69 m | 156,90% |
Effektiewe belastingkoers | 12,86% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 748,75 m | -4,49% |
Totale bates | 2,92 mjd | 3,29% |
Totale aanspreeklikheid | 840,62 m | 3,28% |
Totale ekwiteit | 2,08 mjd | — |
Uitstaande aandele | 56,29 m | — |
Prys om te bespreek | 4,37 | — |
Opbrengs op bates | 1,09% | — |
Opbrengs op kapitaal | 1,15% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 14,91 m | 2 379,97% |
Kontant van bedrywe | 48,10 m | -2,48% |
Kontant van beleggings | -7,78 m | -32,84% |
Kontant van finansiering | -239,00 k | 99,66% |
Netto kontantverandering | 39,89 m | 258,41% |
Beskikbare kontantvloei | 41,60 m | 9,85% |
Meer oor
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. Wikipedia
HUB
Gestig
1981
Webwerf
Werknemers
1 778
